Unichem Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
UNICHEMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.6 pts less than Nifty Microcap 250 and 6.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Unichem Laboratories reported a weak Q1 FY26 with the company slipping into a loss on both consolidated and standalone bases. Consolidated revenue from operations rose ~9% YoY to ₹526.60 crores (vs ₹483.34 crores in Q1 FY25), but expenses grew faster at ~13% to ₹542.44 crores, dragging profit before tax into a loss of ₹9.02 crores (vs a profit of ₹7.81 crores YoY). Consolidated loss after tax stood at ₹10.47 crores, with a basic/diluted EPS of negative ₹1.49 (vs positive ₹0.29 YoY). On a standalone basis, revenue dipped slightly to ₹384.25 crores and the company posted a loss after tax of ₹1.85 crores (vs profit of ₹21.48 crores YoY). The auditor (N. A. Shah Associates LLP) issued an unmodified limited review conclusion. Note: prior-year figures were restated to include the Bayshore Pharmaceuticals USA business acquired from holding company IPCA Laboratories, and the Ireland subsidiary was transferred to IPCA effective April 30, 2025.
The swing to a quarterly loss on rising costs, despite higher consolidated revenue, signals near-term margin pressure and is likely to weigh on the stock in the short term. However, the Bayshore acquisition and Ireland restructuring are related-party transactions with the parent (IPCA) that may reshape the long-term business mix.